9.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$9.38
Aprire:
$9.26
Volume 24 ore:
1.31M
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.05B
Reddito:
-
Utile/perdita netta:
$-294.51M
Rapporto P/E:
-2.5955
EPS:
-3.56
Flusso di cassa netto:
$-244.42M
1 W Prestazione:
-1.70%
1M Prestazione:
-13.08%
6M Prestazione:
-32.65%
1 anno Prestazione:
-78.88%
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Confronta DYN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DYN
Dyne Therapeutics Inc
|
9.24 | 1.33B | 0 | -294.51M | -244.42M | -3.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-24 | Iniziato | Bernstein | Mkt Perform |
2025-06-11 | Ripresa | Raymond James | Outperform |
2025-06-02 | Ripresa | Oppenheimer | Outperform |
2025-05-29 | Iniziato | Evercore ISI | Outperform |
2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
2024-12-13 | Iniziato | Robert W. Baird | Outperform |
2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
2024-04-30 | Iniziato | Morgan Stanley | Overweight |
2024-02-20 | Iniziato | H.C. Wainwright | Buy |
2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2023-02-15 | Iniziato | Oppenheimer | Outperform |
2023-01-26 | Iniziato | Guggenheim | Buy |
2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
2022-07-12 | Iniziato | Raymond James | Outperform |
2020-10-12 | Iniziato | JP Morgan | Overweight |
2020-10-12 | Iniziato | Jefferies | Buy |
2020-10-12 | Iniziato | Piper Sandler | Overweight |
2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional
What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional
What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus
Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha
Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN
Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest
DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance
Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus
Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail
Dyne Therapeutics shares rise 2.08% after-hours following RBC's price target cut to $25. - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
(DYN) Trading Report - news.stocktradersdaily.com
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ATTENTION DYN Shareholders: Lost Money on Dyne Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Petri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debt - The Business Journals
Dyne Therapeutics Announces Closing of Public Offering of Common - GuruFocus
Dyne Therapeutics' $230M Capital Injection: A Strategic Gamble in Rare Neuromuscular Disorders? - AInvest
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $230 Million Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics Announces Closing of Public Offering of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect - ACCESS Newswire
Shareholders Alert: Investigation Into Dyne Therapeutics, Inc. (DYN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Dyne Therapeutics (DYN) Launches $200 Million Public Offering - GuruFocus
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Dyne Therapeutics slides on $200 mln equity raise - TradingView
Dyne Therapeutics, Inc. (DYN) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):